Non-Small Cell Lung Cancer Videos

Videos

Recent Advancements in the Non–Small Cell Lung Cancer Treatment Landscape

07/22/2024

Sandip Patel , MD;

Sandip Patel, MD, discusses the latest updates in the non–small cell lung cancer (NSCLC) treatment landscape.

Sandip Patel, MD, discusses the...

07/22/2024

Journal of Clinical Pathways

Conference Coverage

Subcutaneous vs Intravenous Amivantamab Plus Lazertinib for Patients With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

06/01/2024

Natasha Leighl, MD

Natasha Leighl, MD, discussed results from the phase 3 PALOMA-3 trial which compared subcutaneous and intravenous amivantamab plus lazertinib in patients with advanced, EGFR-mutated non-small cell lung cancer.

Natasha Leighl, MD, discussed...

06/01/2024

Oncology

Sarah Smith, Virginia Cancer Specialists

Videos

Post-Progression and Safety Outcomes With First-Line Amivantamab Plus Lazertinib vs Osimertinib for Advanced NSCLC: Best Management Practices

05/24/2024

Sarah Smith, BD, CNMT, discusses findings from the phase 3 MARIPOSA study exploring post-progression and safety outcomes with first-line amivantamab plus lazertinib vs osimertinib for advanced NSCLC and offers guidance for best management...

Sarah Smith, BD, CNMT, discusses...

05/24/2024

Oncology

Conference Coverage

Should Docetaxel Plus Ramucirumab Be the Standard Second-Line Option for Patients With Non-Small Cell Lung Cancer?

05/15/2024

Edward Garon, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Edward Garon, MD, MS, argued that docetaxel plus ramucirumab should be the standard second-line option for patients with NSCLC.

At the Great Debates and Updates...

05/15/2024

Oncology

Conference Coverage

Non-Surgical Interventions for Patients With Stage 3 Non-Small Cell Lung Cancer

04/27/2024

Featuring Charles Simone, MD

At the Great Debates and Updates in Lung Cancer Meeting in New York, New York, Charles Simone, MD, argued that surgical approaches have a limited role in the treatment of patients with stage 3 non-small cell lung cancer.

At the Great Debates and Updates...

04/27/2024

Oncology

Videos

Amivantamab Plus Chemotherapy Improved Treatment Outcomes Among Patients With Advanced EGFR-Mutated Non-Small Cell Lung Cancer

04/02/2024

Featuring Alex Spira, MD, PhD, FACP

Featuring Alex Spira, MD, PhD, FACP ...

Alexander Spira, MD, PhD, FACP, discussed post-progression results from the phase 3 MARIPOSA-2 trial, as presented at the European Lung Cancer Congress 2024.

Alexander Spira, MD, PhD, FACP,...

04/02/2024

Oncology

Videos

Increasing Biomarker Testing Rates for Patients With NSCLC

12/07/2023

David Waterhouse , MD, MPH;

David Waterhouse, MD, MPH, talks about OHC’s quality improvement project that increased biomarker testing rates for patients with metastatic NSCLC, and shared how the program can be scaled to other practices and other cancers.

David Waterhouse, MD, MPH, talks...

12/07/2023

Journal of Clinical Pathways

Videos

Clinical Value of Timely Targeted Therapy for Patients With Advanced Non–Small Cell Lung Cancer

07/12/2023

Thomas Stricker , MD;

Thomas Stricker, MD, PhD, speaks with the Journal of Clinical Pathways about his research on the clinical impact of the timing of first line targeted therapy in aNSCLC patients with actionable driver oncogenes.

Thomas Stricker, MD, PhD, speaks...

07/12/2023

Journal of Clinical Pathways

Videos

Real-World Response Endpoints in Patients With mNSCLC Treated With Chemotherapy Across Real-World Datasets

07/03/2023

Janet Espirito , PharmD;

Janet L. Espirito, PharmD, Senior Medical Director for Ontada, speaks with the Journal of Clinical Pathways about the significance of her research on real-world response endpoints in patients with mNSCLC treated with chemotherapy across...

Janet L. Espirito, PharmD,...

07/03/2023

Journal of Clinical Pathways

Conference Coverage

Inequities in Next-Generation Sequencing Testing Among Patients With Advanced Non–Small Cell Lung Cancer

06/07/2023

Dr Gregory Vidal, Breast Medical Oncologist, West Cancer Center, Germantown, TN, spoke with the Journal of Clinical Pathways at the ASCO 2023 Annual Meeting about his study on inequities in next-generation sequencing testing by race/ethnicity...

Dr Gregory Vidal, Breast Medical...

06/07/2023

Journal of Clinical Pathways

Current Issue

October 2024

Volume 10

Issue 5

Current Issue

Issue Archive

Special Reports

Sponsored

JCP Special Report

The Value of Tissue-Based Genomic Profiling in Oncology

09/17/2024

Innovations in precision oncology have helped healthcare providers to create more personalized treatment plans and improve patient outcomes. View this special report to learn more.

Innovations in precision...

09/17/2024

Journal of Clinical Pathways

Sponsored

Special Report

Shedding Light on Non-Small Cell Lung Cancer & Its Impact on Patients

04/03/2023

This supplement aims to raise awareness about non-small cell lung cancer (NSCLC) and its impact on patients by providing comprehensive information to help improve early detection and appropriate care.

This supplement aims to raise...

04/03/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Brukinsa® (Zanubrutinib) for Chronic Lymphocytic Leukemia

03/31/2023

In this product monograph, read an interview with Jeff P. Sharman, MD, as he discusses important BRUKINSA® trial data including efficacy, safety, dosing, administration, and other relevant data. These key findings supported the Food and Drug...

In this product monograph, read...

03/31/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

Tumor Lysis Syndrome: Early Diagnosis and Management

01/04/2023

This review summarizes the diagnosis, pathophysiology, and evidence-based guidelines for the prevention and management of tumor lysis syndrome, a common, acute, life-threatening disease primarily in patients with hematologic cancers and solid...

This review summarizes the...

01/04/2023

Journal of Clinical Pathways

Sponsored

JCP Special Report

A Tumor Lysis Syndrome Risk Assessment and Its Impact on Patients

08/09/2022

In an interview with Journal of Clinical Pathways, Nicholas Short, MD, shares objectives on the design and benefits of MD Anderson’s Tumor Lysis Syndrome clinical assessment for patient risk and impact on patient care.

In an interview with Journal of...

08/09/2022

Journal of Clinical Pathways

Updated NCCN Guidelines on B-Cell Lymphomas

Sponsored

JCP Special Report

Overview of the Updated NCCN Guidelines on B-Cell Lymphomas

06/15/2022

Robert Fee ;

Updated multiple times in 2022, the National Comprehensive Cancer Network (NCCN) Guidelines for B-Cell Lymphomas provide recommendations for the prevention, diagnosis, and management of malignancies.

Updated multiple times in 2022,...

06/15/2022

Journal of Clinical Pathways

Sponsored

Special Report

Expanded Indication for Zanubrutinib: Marginal Zone Lymphoma and Waldenström’s Macroglobulinemia

06/10/2022

In an interview with Journal of Clinical Pathways, Mitul Gandhi, MD, reviews the clinical impact and treatment approaches and challenges for patients with marginal zone lymphoma and Waldenström’s macroglobulinemia.

In an interview with Journal of...

06/10/2022

Journal of Clinical Pathways

JCP Special Report

Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group

05/20/2022

Robin T. Zon , MD, FACP, FASCO;

Gordon Kuntz ;

Winston Wong , PharmD;

The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...

The Journal of Clinical Pathways...

05/20/2022

Journal of Clinical Pathways

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

Sponsored

Special Report

Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer

12/15/2021

Deborah Abrams Kaplan ;

NCCN released updates to its practice guidelines on treating triple-negative breast cancer, featuring updates on sacituzumab govitecan recommendations and more.

NCCN released updates to its...

12/15/2021

Journal of Clinical Pathways

Sponsored

Special Report

Navigating the Patient Journey for Unresectable Stage III Non-Small Cell Lung Cancer

09/16/2021

.ryan-test { display: none; } .body-content h3 { font-size: 18px; line-height: 18px; color: #000000; font-weight: 600px; } .related-content { display: none; } .body-content div > div:nth-of-type(3) .paragraph > h3 >...

.ryan-test { display:...

09/16/2021

Journal of Clinical Pathways

Journal of Clinical Pathways Newsletter

Non-Small Cell Lung Cancer Videos

Current Issue

Special Reports

Subscribe

Specialties

Events

Year Round Education

HMP Global Products